Yumanity Therapeutics announced the appointment of Brigitte Robertson, M.D., as chief medical officer. Dr. Robertson brings nearly two decades of clinical and regulatory experience in neurology and psychiatry to her role, most recently serving as the therapeutic area head of neuroscience global clinical development at Takeda (formerly Shire). Prior to her career in the pharmaceutical industry, Dr. Robertson practiced medicine as a board-certified adult, child and adolescent psychiatrist and held a faculty position at Duke University.